<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00580658</url>
  </required_header>
  <id_info>
    <org_study_id>060155</org_study_id>
    <nct_id>NCT00580658</nct_id>
  </id_info>
  <brief_title>Humanitarian Device Exemption</brief_title>
  <acronym>Dystonia IRB</acronym>
  <official_title>Humanitarian Device Exemption for Medtronic Activa Dystonia Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to allow patients to undergo deep brain stimulation (DBS)&#xD;
      surgery for the treatment of dystonia. This is NOT a research study, but rather, a&#xD;
      requirement by the FDA for humanitarian use of the deep brain stimulator device in the&#xD;
      treatment of this rare disorder. Use of DBS for dystonia is approved for humanitarian use by&#xD;
      the FDA in the treatment of chronic, intractable (drug refractory) dystonia, including&#xD;
      generalized and segmental dystonia, hemidystonia, and cervical dystonia (torticollis) in&#xD;
      patients 7 years or older. Thus, this proposal request authorization by the IRB to allow&#xD;
      patients at VUMC to access this HUD therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this IRB approved study is to allow patients to undergo deep brain stimulation&#xD;
      (DBS) surgery for the treatment of dystonia. This is NOT a research study, but rather, a&#xD;
      requirement by the FDA for humanitarian use of the deep brain stimulator device in the&#xD;
      treatment of this rare disorder. Use of DBS for dystonia is approved for humanitarian use by&#xD;
      the FDA in the treatment of chronic, intractable (drug refractory) dystonia, including&#xD;
      generalized and segmental dystonia, hemidystonia, and cervical dystonia (torticollis) in&#xD;
      patients 7 years or older. Thus, this proposal request authorization by the IRB to allow&#xD;
      patients at VUMC to access this HUD therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Dystonia</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic Activa Gpi</intervention_name>
    <description>Activa Therapy, Gpi</description>
    <other_name>DBS</other_name>
    <other_name>Gpi</other_name>
    <other_name>Activa Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients whose ages are in the range of 7 and 99 years old&#xD;
&#xD;
          -  Patients who are diagnosed with chronic, intractable (drug refractory)primary&#xD;
             dystonia, including generalized and or segmental dystonia, hemidystonia, and cervical&#xD;
             dystonia (torticollis)as determined by a neurologist or neurosurgeon.&#xD;
&#xD;
          -  Patients who have failed appropriate medical therapy as determined by the SMD&#xD;
             conference&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients younger than 7 years old&#xD;
&#xD;
          -  Patients who are at significant surgical risk as determined by the neurosurgeon and/or&#xD;
             anesthesiologist.&#xD;
&#xD;
          -  Patients who have not had an adequate trial of medical or non-surgical therapy as&#xD;
             determined by the SMD conference.&#xD;
&#xD;
          -  Patients not deemed good candidates by the SMD conference group.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter E Konrad, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University, Dept. Neurosurgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dario Englot, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University, Dept. Neurosurgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas L Davis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University, Dept. Neurology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Y Fang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University, Dept. Neurology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>December 13, 2007</study_first_submitted>
  <study_first_submitted_qc>December 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2007</study_first_posted>
  <last_update_submitted>October 9, 2019</last_update_submitted>
  <last_update_submitted_qc>October 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Peter Konrad</investigator_full_name>
    <investigator_title>Professor, Director of Functional Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>Dystonia</keyword>
  <keyword>DBS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

